EGFR and non-small cell lung carcinoma: It has been reported that NSCLC patients with EGFR mutation or Murine double minute 2 amplification were not sensitive to immune therapy and even would endure hyperprogressive disease,[18,19] so monotonous immunotherapy or the combination of immune and chemotherapy were not considered in this patient.